Marginal zone lymphoma (MZL) is a slow-growing B-cell cancer that accounts for approximately 7% of all mature non-Hodgkin's lymphomas. It is characterized by a variety of anatomical and clinical manifestations in nodal, splenic and extranodal or mucosa-associated subtypes. For recurrent or refractory forms of MZL, anti-CD20 drugs, the combination of lenalidomide-rituximab and Bruton tyrosine kinase inhibitors (BTK inhibitors) serve as standard treatment options. However, achieving deep and long-lasting remissions of the disease remains challenging. The article is a commentary on CAR T-cell therapy in patients with relapsed or refractory MZL.